Achieve Life Sciences Announces $41.3M Stock Offering

Achieve Life Sciences ( (ACHV) ) has issued an update.

On June 26, 2025, Achieve Life Sciences announced an underwriting agreement to sell 15 million shares of its common stock and accompanying warrants, with the potential to raise approximately $41.3 million. The proceeds are intended to fund the advancement of cytisinicline through FDA approval and for general corporate purposes, potentially impacting the company’s market position in the smoking cessation industry.

The most recent analyst rating on (ACHV) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Achieve Life Sciences stock, see the ACHV Stock Forecast page.

Spark’s Take on ACHV Stock

According to Spark, TipRanks’ AI Analyst, ACHV is a Underperform.

Achieve Life Sciences is navigating typical early-stage biotech challenges, including zero revenue and significant financial losses. While there are promising developments such as the upcoming NDA submission and strong clinical trial progress, these are offset by high operating expenses and dependency on future financing and regulatory approvals. Technical indicators reflect a downward trend, and the valuation remains unattractive with a negative P/E ratio.

To see Spark’s full report on ACHV stock, click here.

More about Achieve Life Sciences

Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline, a plant-based alkaloid, as a treatment for nicotine dependence for smoking cessation. The company is committed to addressing the global smoking health and nicotine dependence epidemic and has submitted a New Drug Application to the FDA for cytisinicline based on successful Phase 3 studies.

Average Trading Volume: 264,818

Technical Sentiment Signal: Sell

Current Market Cap: $131.8M

For an in-depth examination of ACHV stock, go to TipRanks’ Overview page.